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Abstract
Background: In a recent multi-centre Italian survey (2003–2004), conducted in 45 laboratories
throughout Italy with the aim of monitoring microorganisms responsible for severe infections and
their antibiotic resistance, Acinetobacter baumannii was isolated from various wards of 9 hospitals
as one of the most frequent pathogens. One hundred and seven clinically significant strains of A.
baumannii isolates were included in this study to determine the in vitro activity of tigecycline and
comparator agents.
Methods: Tests for the susceptibility to antibiotics were performed by the broth microdilution
method as recommended by CLSI guidelines. The following antibiotics were tested: aztreonam,
piperacillin/tazobactam, ampicillin/sulbactam, ceftazidime, cefepime, imipenem, meropenem
tetracycline, doxycycline, tigecycline, gentamicin, amikacin, ciprofloxacin, colistin, and
trimethoprim/sulphametoxazole. The PCR assay was used to determine the presence of OXA,
VIM, or IMP genes in the carbapenem resistant strains.
Results: A. baumannii showed widespread resistance to ceftazidime, ciprofloxacin and aztreonam
i n  m o r e  t h a n  9 0 %  o f  t h e  s t r a i n s ;  r e s i s t a n ce to imipenem and meropenem was 50 and 59%
respectively, amikacin and gentamicin were both active against about 30% of the strains and colistin
about 99%, with only one strain resistant. By comparison with tetracyclines, tigecycline and
doxycycline showed a higher activity. In particular, tigecycline showed a MIC90 value of 2 mg/L and
our strains displayed a unimodal distribution of susceptibility being indistinctly active against
carbapenem-susceptible and resistant strains, these latter possessed OXA-type variant enzymes.
Conclusion: In conclusion, tigecycline had a good activity against the MDR A. baumannii strains
while maintaining the same MIC90 of 2 mg/L against the carbapenem-resistant strains.
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Background
Acinetobacter baumannii has emerged as one of the most
problematic nosocomial pathogens to eradicate using
available antimicrobial agents, and its occurrence has
increased especially in patients admitted to intensive care
units (ICUs). In a recent Italian survey, this microorgan-
ism ranked third among the most relevant pathogens in
ICUs and was one of the most resistant microrganisms to
all families of antibiotics [1]. The reasons for this emer-
gence in nosocomial settings can be found among: i) its
particular characteristics of being a colonizer of multiple
body sites of hospitalized patients; ii) its ability to survive
for a long time on inanimate surfaces; and iii) its tendency
to be intrinsically resistant and to acquire new resistance
determinants.
The clinical role of A. baumannii has been very controver-
sial: it was considered a colonizer for a long time but
recently, due to the report of severe illness with high asso-
ciated mortality [2] and occurrence of some severe infec-
tions in bacteriemic patients, has been considered – by
some clinicians – an indicator of severity, leading to the
hypothesis that some changes can take place in this strain
i.e. the acquisition of some virulence factors.
Treatment of Acinetobacter spp. infections has been lim-
ited to a few broad-spectrum agents including carbapen-
ems, fluoroquinolones, ceftazidime, trimethoprim/
sulfamethoxazole, sulbactam, amikacin and some tetracy-
clines. As resistance to carbapenems and other alternative
drugs has emerged [3-7], often conferring a multi-drug-
resistance (MDR) phenotype to this microrganism, the
popularity of an old class of drugs, i.e. the polymyxin class
of agents, has increased. However, colistin-resistant A.
baumannii has been recently reported [8,9], and in spite of
documented clinical success, colistin demonstrated dose-
dependent nephrotoxicity [10].
In this context, it is mandatory to look at the activity of
new antimicrobial agents and numerous reports have
indicated that tigecycline, a novel compound belonging
to a new class of antimicrobial agents – glycylcyclines -,
displays inhibitory activity against Acinetobacter spp. [11-
14]. This study sought to determine the in vitro activity of
tigecycline and comparators against Italian carbapenem
resistant and susceptible A. baumannii strains, isolated
throughout Italy during a two-year surveillance study [1].
The presence of carbapenem-resistance genes was also
investigated. These data can add new information to the
in vitro activity of the most used antibiotics against this
sample of epidemiologically representative Italian iso-
lates.
Methods
Bacterial strains
One hundred and seven strains of A. baumannii were col-
lected from 9 out of the 45 centres included in the 2002–
2003 Italian surveillance study on microrganisms respon-
sible for severe infections [1]. The first isolate of each
patient was included in this study. These isolates were
responsible for documented bloodstream and lower res-
piratory tract infections (82 strains), 15 strains were iso-
lated from complicated Skin and Skin Structure Infections
(cSSSI) and 3 strains from Intra-abdominal Infections
(IAIs). The remaining 7 strains were isolated from urinary
catheters. Species identification was centrally performed
as previously described and reconfirmed by conventional
methods using the API 20NE (Bio Merieux – SA- Marcy
l'Etoile – France). Isolates were stored in Mueller-Hinton
broth with 15% glycerol and frozen at -80°C prior to
experiments.
Antimicrobial agents and MIC determinations
MIC determinations were performed by broth microdilu-
tion in cation-adjusted Mueller-Hinton broth in accord-
ance with CLSI guidelines [15]. MICs were interpreted
with category designations according to CLSI criteria [15].
Breakpoints for tigecycline susceptibility were interpreted
according to the FDA breakpoint of 2 mg/L.
Laboratory-grade standard reference powders of the fol-
lowing antimicrobials were obtained and reconstituted
according to the manufacturers' instructions: tigecycline
(Wyeth Research, PA, USA); amikacin, aztreonam, doxy-
cycline, gentamicin, ciprofloxacin, cotrimoxazole, ceftazi-
dime, tetracycline (Sigma Chemical Company, St. Louis,
MO, USA), cefepime (Bruno Farmaceutici SpA Milan,
Italy), ampicillin/sulbactam (Pfizer Italy), piperacillin/
tazobactam (Wyeth Research, PA, USA), imipenem
(Merck & Company, Rathway, NJ, USA), meropenem
(Astra Zeneca, Waltham, MA, USA), and colistin (MP Bio-
medicals, Solon, Ohio, USA). Solutions of tigecycline
were freshly prepared on the day of the experiments to
avoid known degradation problems. All other antibiotics
were freshly prepared as stock solutions and frozen at -
20°C until their use.
Time-kill studies
Five isolates (three imipenem-susceptible and two resist-
ant strains) were chosen for time-kill studies: organisms
were grown on Mueller-Hinton broth for 4 h (log phase of
growth) and were further diluted in 20 ml of the same
medium to yield a concentration of approximately 5 × 105
CFU/ml. Wells containing tigecycline at concentrations
corresponding to the MIC and two and four times the MIC
were tested for each strain. Aliquots (0.1 ml of broth) were
removed from each well and serial dilutions were plated
onto blood-agar plates after 0, 2, 4, 8 and 24 h of incuba-Annals of Clinical Microbiology and Antimicrobials 2008, 7:4 http://www.ann-clinmicrob.com/content/7/1/4
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tion. Colony counts were performed after 24 h of incuba-
tion at 36°C. Bactericidal activity was defined as a ≥3 log10
reduction compared with the initial inoculum [16].
PCR of carbapenem resistance genes
PCR assays were carried out by using previously published
primers and, in particular, for MBL-encoding genes bla-
IMP, and bla-VIM we followed the protocol published by
Pagani L. et al [17], and for amplification of genes encod-
ing oxacillinases (bla-OXA23-like,  bla-OXA24-like,  bla-
OXA51-like and bla-OXA58-like) the protocol published by
Woodford N. et al [18] was used. The PCR assays were per-
formed directly on colonies. PCR products were purified
and sequenced (BMR Bio Molecular Research, Italy).
Results
The 107 strains included in the study were collected from
9 centres in Italy, mainly located in the Central-South area
of the country. Lungs and blood were the most common
sources of the isolates (41.6% of all isolated came from
lower respiratory tract infections, and 20.3% were isolated
from blood cultures). In this survey, A. baumannii was also
isolated from urinary catheters, complicated skin and skin
structure (both 13.8%), and intra-abdominal infections
(2.7%).
The results of the in vitro susceptibility testing, expressed
as distribution, MIC50, MIC90 and percentage of resistance
are presented in Table 1. The vast majority of strains of A.
baumannii  showed a multi-drug resistant phenotype
(MDR), in particular, 53 strains were simultaneously
resistant to three antibiotics, namely fluoroquinolones,
ceftazidime and aminoglycosides or imipenem, while 44
strains were resistant to four antibiotics, the above three
including carbapenems. 17% of strains were resistant also
to ampicillin/sulbactam. More than 90% of strains were
simultaneously resistant to ciprofloxacin, trimethoprim/
sulphametoxazole, aztreonam, and ceftazidime; around
70% of strains were also resistant to gentamicin, ami-
kacin, and tetracycline, while resistance to carbapenems
was 50% for imipenem and 59% for meropenem. Among
the tetracyclines, the unimodal distribution of susceptibil-
ity of tigecycline was comparable with that of doxycycline
(93 and 94% susceptible, respectively). In our sample of
strains colistin was active (106 out of 107 strains were sus-
ceptible). One strain was resistant to this drug, with a MIC
of 16 mg/L.
The molecular characterization of the carbapenem-resist-
ance gene content of the 58 isolates that were resistant to
meropenem is shown in Table 2. The blaOXA51  and
blaOXA58-like, were the most diffused genes: 43 strains car-
ried both these determinants and 14 strains carried the
blaOXA51-like gene. In our sample of carbapenem-resistant
strains, only one carried the blaoxa23-like together with the
blaoxa51 gene; all strains were negative for MBL (blaVIM and
blaIMP) enzymes (table 2). Six out of the 14 strains carrying
the  blaOXA-51-like gene, demonstrated a susceptible or
intermediate level of resistance to imipenem while they
were resistant to meropenem, suggesting that other mech-
anisms can be responsible for carbapenem resistance in
these strains. In the 43 strains carrying the blaOXA51 and
blaOXA58-like genes there is an association between the
presence of the OXA-58 enzyme and resistance to carbap-
enems.
Table 1: Distribution of MIC, MIC50, MIC90 (mg/l) for 107 isolates of Acinetobacter baumannii (MIC50 and MIC90 values are reported in 
BOLD cells and UNDERLINED numbers, respectively).
MIC (mg/l) % of
Antibiotics 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 SI R
Tigecycline 31 5 2 6 5 6 34 9 33 4
Amikacin 27 4 2 16 58 30 0 70
Gentamicin 81 8 4 563 0 24 0 76
Ciprofloxacin 51 11 0 0 509 5
Trimethoprim-
sulfamethoxazole
5 3 11 88 409 6
Aztreonam 31 13 9 9 419 5
Cefepime 82 94 8 13 9 34 44 22
Ceftazidime 41 0 3 409 6
Piperacillin-
tazobactam
5 5 41 24 5 51 5 44
Imipenem 26 9 18 11 39 22 3 3 1 7 5 0
Meropenem 1 5 5 33 7 18 27 11 10 31 59
Doxycycline 1135 7 8 1 31 32 9 41 5
Tetracycline 1 6 7 2 12 13 9 19 31 71 5 1 2 7 3
Colistin 1 111 4 1 9 2 0 3 0 2 0 19 9 0 1
Ampicillin/
sulbactam
1 3 22 19 31 13 7 54 2 7 11 21 7Annals of Clinical Microbiology and Antimicrobials 2008, 7:4 http://www.ann-clinmicrob.com/content/7/1/4
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A preliminary observation on the level of resistance to car-
bapenems demonstrated that meropenem is a more
hydrolysable substrate with respect to imipenem, and in
all cases, tigecycline remained active in all carbapenem-
resistance-strains.
Time-kill studies with increasing concentrations of tigecy-
cline above the MIC, demonstrated that this antibiotic has
a maximal killing effect near the MIC, without any
increased rate at multiples of the MIC (Table 3). Its bacte-
riostatic activity was similar in all strains tested irrespec-
tive of their resistance to other antibiotics such as
carbapenems.
Discussion
Acinetobacter baumannii is one of the most important
nosocomial pathogens, able to cause severe infections,
occurring principally in immunosuppressed patients, in
patients with serious underlying diseases, or subjected to
invasive procedures and treatment with broad-spectrum
antibiotics [19]. This microorganism is also able to spread
in high-risk wards, causing outbreaks. Nevertheless, until
recently, carbapenems represented a viable choice for
treating infections caused by this organism due to a dif-
fused sensitivity to both imipenem and meropenem. In
Italy, until 2000, very few strains were resistant [20], and
only few genotypes appeared to occur in multiple hospi-
tals causing outbreaks [21-26]. The recent Italian survey
previously cited [1] demonstrated that A. baumannii was
the third pathogen for severity in high-risk wards, fre-
quently derived from nosocomial pneumoniae (VAP) or
bacteremia. In our experience, nosocomial isolates of this
microorganism were also co-pathogens in cSSSI and a few
strains also came from IAIs. Approximately half of the 107
single isolates were MDR to three or four classes of antibi-
otics, including carbapenems, while they were almost
fully susceptible to tigecycline, doxycycline and colistin.
In our results, tigecycline is active, with a MIC90 of 2 mg/L
against 93% of strains with maximum killing at the MIC
concentrations.
The activity of tigecycline in our Italian isolates is compa-
rable with that of many other national and global studies
[12,27-29], including the worldwide program
T.E.S.T.(Tigecycline Evaluation and Surveillance Trial,
[12] that reported a MIC90 value of 1 mg/L for a large
number of A. baumannii isolates (4353) worldwide. The
same study reported the isolation of 14.8% imipenem-
resistant strains. Our data are also in line with the results
obtained in other European studies [30,31] in which tige-
cycline demonstrated its activity with MIC90 of 2 mg/L
against strains showing a multiple resistance phenotype.
A. baumannii isolates resistant to various classes of antibi-
otics are emerging worldwide, and the recent resistance or
reduced susceptibility to carbapenems, is considered a
serious clinical problem due to the role of first choice ther-
apy that these drugs have had until now.
Numerous mechanisms, including decreased permeabil-
ity, efflux pump overexpression, and carbapenemase pro-
duction, can be responsible for the resistance to
carbapenems [7,32,33]. Class B (IMP and VIM enzymes)
and D (oxacillinases) beta-lactamases are the most impor-
tant group of enzymes able to hydrolyze carbapenems:
although MBLs are not the predominant enzymes in A.
baumannii, several IMP-enzymes have been described in
various countries [34-37] while VIM-1, first identified in
Table 2: Tigecycline in carbapenem-resistant isolates carrying different OXA-like genes
BlaOXA 
genes
N. of 
strains
Imipenem mg/L Meropenem mg/L Tigecycline mg/L
≤48 ≥16 ≤48 ≥16 ≤2 ≥ 4
OXA-23/
OXA-51
100101010
O X A - 5 1 1 4 338001 4 1 2 2
OXA-51/
OXA-58
4 32 2 3 90 0 4 34 12
Table 3: Time kill results, expressed as average reduction of log10 of CFU/ml, of tigecycline against five A. baumannii strains with 
different susceptibilities to carbapenems.
Concentration of 
tigecycline
2  h4  h8  h2 4
MIC 0.6 × 10-1 3 × 10-2 3 × 10-2 3 × 10-2
2 × MIC 0.8 × 10-1 2.4 × 10-2 1.3 × 10-2 1.4 × 10-2
4 × MIC 1 × 10-1 1.4 × 10-2 1.2 × 10-2 1.2 × 10-2Annals of Clinical Microbiology and Antimicrobials 2008, 7:4 http://www.ann-clinmicrob.com/content/7/1/4
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Italy in a strain of P. aeruginosa [38], is now reported in
Korea [39], in Poland [40] and, as sporadic isolates, in
many other parts of the world. Most worrisome are the
carbapenemase-hydrolyzing oxacillinase (OXA) clusters
that have been identified in A. baumannii in nine major
subgroups [7,41,42], including the most diffused
throughout the world OXA-23, OXA-24, OXA-51, OXA-58
enzymes and their variants [43]. The significant contribu-
tion of these enzymes to carbapenem resistance in A. bau-
mannii has been emphasized, particularly when they are
accompanied by ISAba1 and ISAba3 in the naturally occur-
ring plasmid [44], due to the fact that these sequences can
provide the promoter required for expression of linked
antibiotic-resistance genes. The OXA-51/69-like beta-
lactamases are, instead, "naturally occurring" chromo-
somal enzymes in this species, isolated from four conti-
nents, and their expression varies according to the
presence of ISAba1 as previously discussed [45]. All these
enzymes have been found in different isolates from vari-
ous countries [24,46-49]. In our strains, OXA-51 alone or
associated with other enzymes was found. As recently sug-
gested [32], these enzymes are very poor carbapenemases
and may be natural chromosomally encoded in the vast
majority of A. baumannii isolates, regardless of their sus-
ceptibility or resistance to carbapenems. OXA-58 enzymes
are the most diffused oxacillinases in 43 strains of A. bau-
mannii. As recently demonstrated, these enzymes may
contribute to carbapenem resistance [32,45], although it
cannot be excluded that other mechanisms may addition-
ally affect the activity of these drugs.
The recent emergence of high-resistance rates to tigecy-
cline in multiple clones of MDR strains is also cause for
concern. Various Authors [50-52] have reported a few
cases of high tigecycline-resistance in nosocomial isolates:
the involvement of an overexpression of the AdeABC
multidrug efflux pump in the decreased susceptibility of
tigecycline in these strains was postulated [52,53]. To
date, tigecycline has been approved for the treatment of
complicated intra-abdominal and complicated skin and
skin structure infections; the well documented activity of
this drug against A. baumannii isolates and the high con-
centration reached by this drug in alveolar cells (77.5 fold
higher than serum)[29], have indicated its use in infec-
tions sustained by these MDR microorganisms [54],
despite the lack of approved clinical indications and crite-
ria for in vitro susceptibility testing. In this situation, due
to the importance that tigecycline can have in the treat-
ment of MDR A. baumannii infections, it is absolutely
mandatory to monitor isolates for evidence of acquired
microbiological resistance, requiring further investiga-
tions to understand better all the possible mechanisms
underlying this phenomenon.
Conclusion
Our results have shown that the MDR resistance pheno-
type is very diffused in A. baumannii isolated from severe
infections in Italy. We have documented that almost half
of the strains are also resistant to carbapenems and, as
published by other Authors [55], also colistin has not
escaped development of resistance: in fact, we isolated
one strain resistant to this drug. Carbapenem-resistance in
these strains is due to the presence of three different oxa-
cillinases and the most diffused hydrolytic enzymes are
the OXA-51/OXA-58 enzymes, carried in 43 strains. Tige-
cycline shows a potent antibacterial activity with a unimo-
dal distribution of MIC and a MIC90 of 2 mg/L; the drug
has indeed a bacteriostatic effect at the MIC concentra-
tion, and its activity is not influenced by the other mech-
anisms of resistance carried in these microorgansims,
including the resistance to carbapenems. Furthermore
recent studies demonstrated that tigecycline achieved
maximal killing near the MIC in this species and concen-
tration escalation studies demonstrated that this drug
needs to approach concentrations higher than those cur-
rently achieved in the bloodstream to adequately treat A.
baumannii infections [13].
These in vitro results, obtained in a representative sample
of Italian isolates – all from documented severe infections
– need to be confirmed by the clinical efficacy of this drug
from Phase 3 clinical trials regarding the treatment of
nosocomial pneumonia and other infections sustained by
this microrganism. For the moment, the evaluation of the
microbiological and pharmacological profile of tigecy-
cline in each patient and the careful assessment of suscep-
tibility can assist physicians in deciding on tigecycline use.
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